Scohia Pharma raises ¥3B (~$20M) to advance rare-disease and obesity programmes
What's the deal? Scohia Pharma, a Japanese biotech startup spun out of Takeda Pharmaceutical in 2017, has raised ¥3B (~$20M) through a third-party share allocation. The Fujisawa-based company specialises in endocrine, cardiovascular, renal, and metabolic diseases, with a focus on rare conditions and obesity.
Beyond Next VenturesDealroom has a profile for this one. Try Dealroom → led the round as a new investor, joined by fellow newcomers DCI Partners, Kyoto Capital PartnersDealroom has a profile for this one. Try Dealroom →, Bio-Site Capital, and FRONTEO. Existing backers DBJ CapitalDealroom has a profile for this one. Try Dealroom →, SBI InvestmentDealroom has a profile for this one. Try Dealroom →, Tohoku University Venture PartnersDealroom has a profile for this one. Try Dealroom →, and KSP also participated.
The funds will primarily advance two programmes that have completed Phase 1 trials: SCO-240, targeting growth hormone deficiency short stature, and SCO-792, targeting autosomal dominant polycystic kidney disease (ADPKD). Both conditions are designated rare diseases in Japan.
Why now? Scohia has built momentum through a string of licensing deals. It out-licensed SCO-483 to Neurocrine BiosciencesDealroom has a profile for this one. Try Dealroom → — described by SBI Investment as the largest such deal by a private Japanese biotech — and signed separate agreements with Huadong MedicineDealroom has a profile for this one. Try Dealroom → and Kuria Therapeutics. It also struck a strategic collaboration with Celltrion in obesity, where it has already identified a lead compound, SCO-940.
Beyond Next Ventures noted that the round exceeded its initial target despite a tough fundraising climate for Japanese drug discovery startups, calling it "a very positive signal" for the country's biotech ecosystem.
What could go wrong? Both lead programmes remain early-stage. Phase 1 completion confirms basic safety, but the long road through Phase 2 and 3 trials carries high failure risk — particularly in rare diseases, where patient recruitment is difficult and timelines stretch out. Japan's biotech funding environment remains constrained compared with the US, which could complicate future rounds if clinical milestones slip.
The signal: Scohia's ability to exceed its fundraising target — at a time when Japanese drug discovery startups face a constrained capital environment — speaks to the pull of a proven out-licensing track record, particularly the landmark Neurocrine deal. With Dealroom classifying the company at "breakout" stage, this round suggests that investor confidence in Japan's biotech carve-out model is firming, especially where global pharma partnerships can de-risk early clinical assets.
Read more: PR TIMES
